Soleno Therapeutics Inc (SLNO)

Soleno Therapeutics Inc Aktie (SLNO) Neueste Nachrichten

Soleno Therapeutics Stands with the Prader-Willi Syndrome Community

GlobeNewswire Inc.

Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock

GlobeNewswire Inc.

Soleno Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire Inc.

US Stocks Kick Off The Week In The Green, Tesla Rockets On China's FSD Approval, Yen Rallies: What's Driving Markets Monday?

Benzinga

Why Soleno Therapeutics Stock Is Skyrocketing Today

The Motley Fool

Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)

GlobeNewswire Inc.

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

GlobeNewswire Inc.

Soleno Therapeutics, Inc. (SLNO) Is a Great Choice for 'Trend' Investors, Here's Why

Zacks Investment Research

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Here's Why Momentum in Soleno Therapeutics, Inc. (SLNO) Should Keep going

Zacks Investment Research

Here's What Could Help Soleno Therapeutics, Inc. (SLNO) Maintain Its Recent Price Strength

Zacks Investment Research

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Forget The Magnificent 7: Did Anyone Back These 1,000% Gainers In 2023?

Benzinga

The best-performing stock of the year rose nearly 10-fold, while the 2nd-best averted disaster to surge 1,000% in a wild 2023

MarketWatch

The best-performing stock of the year rose nearly 10-fold, while the 2nd-best averted disaster to surge 1,000% in a wild 2023

MarketWatch

The best-performing stock of the year rose nearly 10-fold, while the 2nd-best averted disaster to surge 1,000% in a wild 2023

MarketWatch

The best-performing stock of the year rose nearly 10-fold, while the 2nd-best averted disaster to surge 1,000% in a wild 2023

MarketWatch

Why Soleno Therapeutics Stock Ticked Higher on Thursday

The Motley Fool

4 Analysts Have This to Say About Soleno Therapeutics

Benzinga